Congratulations to ToleRaM Nanotech, LLC, flagged as a finalist by BioProcess International (BPI) as an Emerging Company to watch!

ToleRaM Nanotech was developed through a collaboration between the MUSC Radiology and Surgery Departments as a platform to synthesize and market novel delivery devices wherein antirejection drugs are encapsulated in a biologically inert nanoparticle device and delivered in a focused manner to a transplanted organ with a triggered-release.

The devices marketed by ToleRaM capitalize on a growing appreciation that immune suppression at the graft level may have more profound effects on rejection than does systemic immunosuppression.